Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Development of a Computer-aided Diagnostic System for Detecting Multiple Sclerosis Using Magnetic Resonance Images.
Study shows promising efficacy for peginterferon beta-1a in multiple sclerosis
Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis.
Systematic approaches to central nervous system myelin.
Transcriptional enhancers: from properties to genome-wide predictions.
PLEGRIDY™ (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients
Phenytoin protects central axons in experimental autoimmune encephalomyelitis.
Recent Gains in Clinical Multiple Sclerosis Research Review.
Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy.
Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study.
Safety and efficacy of fingolimod in treatment-naïve multiple sclerosis patients.
Substance Name: Naltrexone
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice.
Drug record: Amiloride
Association of multiple sclerosis susceptibility variants and early attack location in the CNS.
Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis.
Association mapping of disease loci, by use of a pooled DNA genomic screen.
Cognitive and Behavioral Outcomes in Individuals With a History of Acute Disseminated Encephalomyelitis (ADEM).
Motor programme activating therapy influences adaptive brain functions in multiple sclerosis: clinical and MRI study.
N-Acetylcysteine amide: A Derivative to Fulfill the Promises of N-Acetylcysteine.
The effect of supported standing in adults with upper motor neurone disorders: a systematic review.
Genzyme to Resubmit LemtradaTM Application for FDA Review
Genzyme receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) application
COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.

Pages